Outcome of Emergent ABO-Incompatible Liver Transplantation is Acceptable but at the Cost of Higher Diffuse Intrahepatic Biliary Stricture: A Single-Center, Retrospective Study
Retrospective study finds lower survival rates in emergent ABO-incompatible liver transplantation, suggesting strategies are needed to reduce complications.
Key Points
This study aimed to characterize the outcomes of emergent ABO-incompatible liver transplantation and identify predictors of survival.
Analyzed a cohort of 110 ABO-incompatible liver transplant recipients with rituximab-based desensitization.
Followed up recipients for survival rates at 1, 3, and 5 years.
Conducted propensity score matching with a control group of 110 ABO-compatible recipients.
1-year survival rate: ABO-I group 74.0% vs ABO-C group 88.0% (P = 0.024).
3-year survival rate: ABO-I group 68.5% vs ABO-C group 83.0% (P = 0.024).
Identified risk factors for survival including age > 65 years, liver cancer prior to transplant, and incidence of diffuse intrahepatic biliary stricture.